Successful transition from Treprostinil to Selexipag in patient with severe pulmonary arterial hypertension
Abstract Background In this report, we describe the first successful case of transition from subcutaneous administration of treprostinil to selexipag in a patient with severe pulmonary arterial hypertension (PAH), by evaluating hemodynamic changes and exercise tolerance. Case presentation A 38-year-...
Main Authors: | Asuka Furukawa, Yuichi Tamura, Hiroya Iwahori, Masato Goto, Narutaka Ohashi, Teruo Okabe, Akio Kawamura |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2017-10-01
|
Series: | BMC Pulmonary Medicine |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12890-017-0480-9 |
Similar Items
-
Selexipag in the management of pulmonary arterial hypertension: an update
by: Coghlan JG, et al.
Published: (2019-08-01) -
Therapeutic strategies in pulmonary hypertension
by: Leonello eFuso, et al.
Published: (2011-04-01) -
New treatment options for pulmonary arterial hypertension — the first selective IP-receptor agonist selexipag
by: N. V. Ilyin, et al.
Published: (2019-12-01) -
The use of combination therapy in pulmonary arterial hypertension: new developments
by: N. Galiè, et al.
Published: (2009-09-01) -
Transition from selexipag to oral treprostinil in a patient with pulmonary arterial hypertension
by: Ifeoma Oriaku, et al.
Published: (2020-03-01)